Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke.
Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke.
复制标题
DOI：
10.1111/j.1749-6632.2010.05733.x
复制
发表时间：
2010-10
影响因子：
5.2
通讯作者：
Rondina MT
中科院分区：
文献类型：
--
作者：
Franks ZG;Campbell RA;Weyrich AS;Rondina MT
中风是一种常见且往往致命的事件，并且在幸存者中，它伴随着高复发风险。缺血性中风与血小板活性异常和血栓形成有关。除了在急性血栓形成中的作用外，血小板还充当血管系统内白细胞的桥梁。髓系白细胞是动脉粥样硬化和动脉粥样硬化血栓形成的关键介质。血小板和白细胞之间的相互作用促进炎症和血栓形成环境，影响病变进展，促进斑块破裂，并触发血栓形成和栓塞。因此，抗血小板药物，包括阿司匹林、双嘧达莫和氯吡格雷，是大多数有卒中史患者的推荐治疗。除了减轻血栓形成外，抗血小板药物还对炎症具有直接和间接的作用，这可能会转化为增强的临床疗效。
Stroke is a common and often fatal event, and, in survivors, it is accompanied by a high risk of recurrence. Ischemic stroke is associated with abnormal platelet activity and thrombus formation. In addition to their roles in the development of acute thrombi, platelets serve as a bridge for leukocytes within the vasculature. Myeloid leukocytes are critical mediators of atherosclerosis and atherothrombosis. Interactions between platelets and leukocytes foster an inflammatory and thrombotic milieu that influences lesion progression, facilitates plaque rupture, and triggers thrombus formation and embolization. Accordingly, antiplatelet agents, including aspirin, dipyridamole, and clopidogrel, are recommended therapies for most patients with a history of stroke. In addition to mitigating thrombosis, antiplatelet drugs have direct and indirect effects on inflammation, which may translate to enhanced clinical efficacy.
登录
查看更多内容
影响因子：
15.9
作者：
Dong, ZM;Chapman, SM;Wagner, DD
通讯作者：
Wagner, DD
影响因子：
37.8
作者：
Koyama, H;Maeno, T;Nishizawa, Y
通讯作者：
Nishizawa, Y
影响因子：
2.9
作者：
Diener, Hans-Christoph;Sacco, Ralph;Yusuf, Salim
通讯作者：
Yusuf, Salim
影响因子：
20.3
作者：
Burger, PC;Wagner, DD
通讯作者：
Wagner, DD
影响因子：
37.8
作者：
Dong, ZM;Brown, AA;Wagner, DD
通讯作者：
Wagner, DD